Experimental Nuclear Medicine Meets Tumor Biology

Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence of different (pre)clinical disciplines that openly share their knowledge and methodologies. This review sheds light on the differential perception of biomarkers and gives an overview of currently used models in tracer development and approaches for biomarker discovery.

Automated summary

Personalized treatment of cancer requires specific and validated biomarkers for tumor diagnosis and therapy. Translational preclinical models that accurately recapitulate human diseases are needed for the development and validation of these biomarkers, and there is a need for collaboration and knowledge sharing among different disciplines.